These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

667 related items for PubMed ID: 15877299

  • 41. Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
    Athyros VG, Papageorgiou AA, Demitriadis DS, Kontopoulos AG.
    Curr Med Res Opin; 2001; 17(4):267-72. PubMed ID: 11922400
    [Abstract] [Full Text] [Related]

  • 42. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
    Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS.
    Am Heart J; 2004 Oct; 148(4):635-40. PubMed ID: 15459594
    [Abstract] [Full Text] [Related]

  • 43. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
    Puccetti L, Bruni F, Bova G, Cercignani M, Palazzuoli A, Console E, Auteri A, Pasqui AL.
    Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702
    [Abstract] [Full Text] [Related]

  • 44. Targeting vascular risk in patients with metabolic syndrome but without diabetes.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Peletidou A, Kleta D, Karagiannis A, Kakafika AI, Tziomalos K, Elisaf M.
    Metabolism; 2005 Aug; 54(8):1065-74. PubMed ID: 16092057
    [Abstract] [Full Text] [Related]

  • 45. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T, Akar Bayram N, Kayhan T, Canbay A, Sahin D, Durmaz T, Ozdemir O, Aydoğdu S, Diker E.
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [Abstract] [Full Text] [Related]

  • 46. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC.
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [Abstract] [Full Text] [Related]

  • 47. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC, Wang F, Zhou Q, Li YH, Li YG, Wang HP, Chen SY.
    Chin Med J (Engl); 2009 Jul 20; 122(14):1615-20. PubMed ID: 19719960
    [Abstract] [Full Text] [Related]

  • 48. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

  • 49. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S, Hilleman D.
    Pharmacotherapy; 2008 May 22; 28(5):570-5. PubMed ID: 18447655
    [Abstract] [Full Text] [Related]

  • 50. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
    Fogari R, Marasi G, Vanasia A, Zoppi A, Lusardi P, Preti P.
    Int J Clin Pharmacol Ther; 1997 Feb 22; 35(2):61-4. PubMed ID: 9147709
    [Abstract] [Full Text] [Related]

  • 51. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul 22; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 52. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.
    Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB.
    Am Heart J; 2006 Nov 22; 152(5):982.e1-5. PubMed ID: 17070175
    [Abstract] [Full Text] [Related]

  • 53. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
    Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA.
    Pharmacotherapy; 2005 Mar 22; 25(3):335-44. PubMed ID: 15843280
    [Abstract] [Full Text] [Related]

  • 54. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.
    Clin Ther; 2007 Nov 22; 29(11):2365-73. PubMed ID: 18158077
    [Abstract] [Full Text] [Related]

  • 55. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ, Li YS, Chu JM, Zhang CY, Wang Y, Huang Y, Chen J, Yuan JQ, Huang YL.
    Clin Chim Acta; 2006 Apr 22; 366(1-2):269-73. PubMed ID: 16343471
    [Abstract] [Full Text] [Related]

  • 56. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG.
    Am J Cardiol; 2001 Jan 01; 87(1):44-8. PubMed ID: 11137832
    [Abstract] [Full Text] [Related]

  • 57. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, DISCOVERY PENTA investigators.
    Curr Med Res Opin; 2005 Aug 01; 21(8):1307-15. PubMed ID: 16083541
    [Abstract] [Full Text] [Related]

  • 58. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG.
    Diabetes Care; 2002 Jul 01; 25(7):1198-202. PubMed ID: 12087019
    [Abstract] [Full Text] [Related]

  • 59. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
    Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS.
    J Cardiovasc Risk; 1999 Apr 01; 6(2):113-6. PubMed ID: 10353071
    [Abstract] [Full Text] [Related]

  • 60. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B, Jeamanukulkit N, Piamsomboon C, Chawantanpipat C, Khanacharoen I.
    J Med Assoc Thai; 2004 Nov 01; 87(11):1281-5. PubMed ID: 15825700
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.